BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Other financings of public biotechnology companies in February 2020
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Other financings of public biotechnology companies in February 2020
March 6, 2020
No Comments
Private placements and other private financings of public biopharma companies, including: Acerus, Adamis, Aeterna Zentaris, Agile, Algernon, Alimera, Aptorum, Arch, Armata, Avadel, Biomerica, Cidara, Cocrystal, Collegium, Collplant, Cortexyme, CTI, Curis, Daré, Enlivex, E-therapeutics, Genmab, Genprex, Hemostemix, Kali-Extracts, Lidds, Lipocine, Mereo, Moleculin, Navidea, Novacyt, Orphazyme, Outlook, Phio, Promis, Redhill, Redx, Revance, Revive, Spero, Syndax, Syros, Valneva, Vaxil, Xortx, Zelira.
BioWorld
Analysis and data insight